WASHINGTON (dpa-AFX) - Revvity, Inc. (RVTY) announced a strategic collaboration with Profluent, resulting in a simplified access for customers to a therapeutically relevant base editing toolkit. The new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing.
The company said the combination of the Pin-point platform and a curated selection of Profluent's adenine deaminases are available from Revvity through bundled licensing to significantly expand the number of disease-related mutations that could be addressed using the Pin-point platform and accelerate adoption by therapeutic developers.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
